Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 83

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 4
Chunk 83
---
, DSHEA, and other federal and state statutes and requirements, including for failing to adhere to current GPMs,
making false or misleading product statements, providing inaccurate ingredient identity and potency, and failing to control or disclose
allergens, contaminants, residues and adulterants, as well as for state common and statutory laws regarding deceptive trade practices.

We
could also be the target of claims relating to false or deceptive advertising in connection with the marketing and advertising of the
products we sell, including under the auspices of the FTC, the consumer protection statutes of some states as well as certain non-government
watchdog groups and class action law firms. In addition, the FDA has aggressively enforced its regulations with respect to structure/function
claims (e.g., “calcium builds strong bones”), nutrient content claims (e.g., “high in antioxidants”)
and other claims that impermissibly suggest therapeutic benefits In addition, the number of private consumer class actions relating to
false or deceptive advertising against cosmetic, food, beverage and nutritional supplement manufacturers has increased in recent years.
These events could interrupt the marketing and sales of products in our stores, including our private label products, severely damage
our brand reputation and public image, increase the cost of products in our stores, result in product recalls or litigation, and impede
our ability to deliver merchandise in sufficient quantities or quality to our stores, which could result in a material adverse effect
on our business, financial condition, results of operations and cash flows.

The
global nutraceutical market is highly competitive, with many brands offering products that are similar to Nugevia. Failure to differentiate
from competitors could limit market penetration and revenue potential.

The
global nutraceutical market, valued at $451.7 billion in 2023, is highly competitive, with established players like Nestlé Health
Science, Amway, and smaller niche brands vying for market share. Nugevia’s reliance on resveratrol, despite JOTROL™’s
enhanced bioavailability, faces skepticism due to past studies questioning resveratrol’s efficacy and may require additional clinical
data. Convincing consumers and healthcare professionals of Nugevia’s superior performance will require effective marketing. Failure
to differentiate from competitors offering similar longevity or beauty-from-within products could limit market penetration and revenue
potential.

The
Company is dependent on certain proprietary supply-chain vulnerabilities with operational and supply chain risks.

The
Company’s dependence on proprietary technology like JOTROL™ and partnerships, such